RxDoctor Payments Data

Katherine Yarborough, DO

Psychiatry · Santa Cruz, CANPI 1043304983

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 58 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$284
  • Alkermes, Inc.$254
  • Johnson & Johnson$227
  • Sunovion Pharmaceuticals Inc.$227
  • AbbVie$177
  • Vanda Pharmaceuticals Inc.$123
  • plus $187 from 3 others

What the payments were for

  • Food & beverage$1,46599%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,477 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$2,080
Medicare patients
13
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole11$29,057
Lurasidone Hcl20$15,491
Quetiapine Fumarate79$858
Buspirone Hcl41$577
Aripiprazole12$479
Olanzapine29$476
Clozapine17$450
Haloperidol15$405
Divalproex Sodium12$396
Duloxetine Hcl29$269
Hydroxyzine Pamoate25$268
Trazodone Hcl43$259
Haloperidol Decanoate13$200
Venlafaxine Hcl ErVenlafaxine Hcl16$199
Risperidone21$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$91$29,05711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →